股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 中科生物控股有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01237 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,000,000 | HKD | | 0.5 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 200,000,000 | HKD | | 0.5 | HKD | | 100,000,000 | 本月底法定/註冊股本總額： HKD 100,000,000 第 1 頁 共 1 ...

Core Viewpoint - Ningxia Zhongke Biotechnology Co., Ltd. has successfully applied to revoke the delisting risk warning after the court terminated its restructuring process, allowing the company to continue trading under other risk warnings [2][3]. Group 1: Stock Trading and Risk Warnings - The delisting risk warning was lifted on January 12, 2026, and the stock will be traded under the name "ST Ningke" starting January 14, 2026, after a one-day suspension on January 13, 2026 [2][4]. - The stock price will still be subject to a daily fluctuation limit of 5% as it remains on the risk warning board [2]. Group 2: Financial Performance and Other Risks - The company has faced continuous losses, with a net profit of -53,890.69 million yuan for the year 2024, and a net profit of -40,467.35 million yuan after deducting non-recurring gains and losses [5]. - The company has been under other risk warnings since April 8, 2024, due to its subsidiary entering a production halt and ongoing uncertainties regarding sustainable operational capabilities [5][6]. - As of the third quarter of 2025, the company reported revenue of 32,735.24 million yuan and a net profit attributable to shareholders of -25,097.92 million yuan, with net assets of -17,918.57 million yuan [7].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中科生物控股有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01237 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,000,000 | HKD | | 0.5 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 200,000,000 | HKD | | 0.5 | HKD | | 100,000,000 | 本月底法定/註冊股本總額： ...

Core Viewpoint - Ningxia Zhongke Biological Technology Co., Ltd. is facing significant financial distress, having been ruled by the court to terminate its restructuring process and enter the execution phase of its restructuring plan, which poses a risk of bankruptcy if the plan is not executed successfully [2][5][9]. Group 1: Financial Performance - The company reported a net profit attributable to shareholders of -53.89 million yuan for the year 2024, with a net profit of -40.47 million yuan after deducting non-recurring gains and losses [3][7]. - For the third quarter of 2025, the company achieved an operating income of 32.74 million yuan, with a net profit attributable to shareholders of -25.10 million yuan and a net asset value of -17.92 million yuan [3][7]. Group 2: Regulatory Actions - The company received an administrative penalty from the China Securities Regulatory Commission (CSRC) on April 3, 2025, which has led to additional risk warnings on its stock according to the Shanghai Stock Exchange regulations [4][8]. - The stock has been under other risk warnings since April 8, 2024, due to the suspension of operations at its subsidiary, Zhongke New Materials, which has recently resumed production but remains uncertain regarding sustainable operational capacity [2][7]. Group 3: Market Activity - The company's stock has experienced a continuous trading halt for seven consecutive trading days, with a cumulative increase of 40.49% [4][10]. - Despite the recent stock price volatility, the company's fundamental situation has not changed significantly, and there are no undisclosed major information [4][10].

Group 1 - The top gainers in the Hong Kong stock market include Huameilole (08429.HK) with a rise of 45.28%, Gaokeqiao (09963.HK) up by 44.44%, and Yida China (03639.HK) increasing by 36.36% [1][2] - Other notable gainers are Senmei Holdings (00756.HK) with a 31.43% increase, Zhihua Group (01842.HK) rising by 29.41%, and Xietong Communication (01613.HK) up by 13.92% [1][2] - Additional companies showing significant gains include Aochuan Thinking Holdings (08091.HK) with a 12.50% rise, Futong Technology (00465.HK) increasing by 12.28%, and Zhongke Biological (01237.HK) up by 11.69% [1][2] - The last in the top ten gainers is Gaoyuan Zhibao (08402.HK) with an increase of 11.03% [1][2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1237） 澄清公告 授出股份獎勵 茲提述中科生物控股有限公司（「本公司」）於二零二五年八月八日及二零二五年 十二月五日刊發的公告（「該等公告」）及本公司於二零二五年九月二十二日刊發 的通函（「通函」），內容有關根據股份獎勵計劃發行新股份及授出股份獎勵。本公 告所用詞彙與該等公告及通函所界定者具有相同涵義。 本公司謹此澄清，向承授人授出股份獎勵後，根據二零二五年股份獎勵計劃，計劃 授權限額及服務提供商分項限額項下可供日後授出的股份數目將為3,705股。 CHINA ENVIRONMENTAL TECHNOLOGY AND BIOENERGY HOLDINGS LIMITED 中科生物控股有限公司 中科生物控股有限公司 主席 謝清美 中國，漳平，二零二五年十二月十一日 於本公告日期，執行董事為謝清美女士及吳哲彥先生及獨立非執行董事為謝國興 先生、鄭冰倩女士及吳麗 ...

中科生物(01237)发布公告，公司根据2025年股份奖励计划的条款向11名承授人授出合共960万股奖励股 份，惟须待承授人接纳方可作实。授予承授人的每份股份奖励均代表于其归属日收取一股股份的权利。 ...

智通财经APP讯，中科生物(01237)发布公告，公司根据2025年股份奖励计划的条款向11名承授人授出合 共960万股奖励股份，惟须待承授人接纳方可作实。授予承授人的每份股份奖励均代表于其归属日收取 一股股份的权利。 ...

格隆汇12月5日丨中科生物(01237.HK)公告，于2025年12月1日，公司根据2025年股份奖励计划的条款向 11名承授人授出合共960万股奖励股份，惟须待承授人接纳方可作实。授予承授人的每份股份奖励均代 表于其归属日收取一股股份的权利。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 CHINA ENVIRONMENTAL TECHNOLOGY AND BIOENERGY HOLDINGS LIMITED （於開曼群島註冊成立的有限公司） 中科生物控股有限公司 | 授出日期： | 二零二五年十二月五日 | | --- | --- | | 承授人： | 本集團11名經選定僱員 | | 授出的股份獎勵數目： | 合共9,600,000份股份獎勵 | | 所授出股份獎勵的購買價： | 零 | | 股份於授出日期的收市價： | 每股股份0.52港元 | | 歸屬期： | 100% 的股份獎勵將於自授出日期起計第一個週年 | | | 之日歸屬。 | 惟董事會可全權酌情決定該等股份獎勵或其任何 部分應予歸屬。 1 表現目標： 授出的股份獎勵並無附帶表現目標。 薪酬委員會知悉，二零二五年股份獎勵計劃的目的 為就合資格參與者對本集團的貢獻為其提供保留 激勵或獎勵，吸引合適人才以促進本集團發展，並 使承 ...